Search form


Press Releases

Axcan Pharma to Host Analyst / Investor Luncheon at Newly Expanded Head Office in Mont-St-Hilaire

Sep 09, 2004 - 12:00 ET

Axcan Pharma to Host Analyst / Investor Luncheon at Newly Expanded Head Office in Mont-St-Hilaire

("Axcan" or the "Company") announced today its upcoming Analyst/Investor
Luncheon, Friday, September 17, 2004, to be held in its newly expanded head
office in Mont-St-Hilaire.

    Mr. Leon Gosselin, President and CEO, will be present at the event as
well as Mr. David Mims, Executive Vice President and COO, who will present a
guidance for fiscal 2005.

    The event will include presentations by world renowned experts in their
respective fields. They will discuss the disease states that underlie each
selected Axcan project as well as the data collected to date and the related
future clinical implications. Axcan's clinical research program will be
highlighted briefly following each presentation.

    The meeting will be co-chaired by Dr. Richard H. Hunt, Professor of
Medicine, Division of Gastroenterology at McMaster University Medical Center,
Hamilton, Canada, and Dr. François Martin, Senior Vice-President of Scientific
Affairs, Axcan Pharma. Other faculty members will be: Dr. Rajiv Jalan, Senior
Lecturer in Hepatology at the Institute of Hepatology in London, UK, and Dr.
Steve Pereira, Senior Lecturer in Hepatology and Gastroenterology also at the
Institute of Hepatology in London, as well as Dr. Kenneth D. Setchell,
Professor of Pediatrics, at the Children's Hospital Medical Center in
Cincinnati, USA.

    An audio webcast will be available live and archived for 30 days on the
Axcan website at .

    Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. Axcan markets a broad line of prescription products sold
for the treatment of symptoms in a number of gastrointestinal diseases and
disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

Julie M. Thibodeau, Manager, Investor 
Relations, Axcan Pharma Inc., (450) 467-5138 ext. 2062,